| Market Cap | 24.56M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.98M | Forward P/E | 3.74 | EPS next Y | - | 50D Avg Chg | 2.00% |
| Sales | 5.42M | PEG | - | EPS past 5Y | 24.07% | 200D Avg Chg | -39.00% |
| Dividend | N/A | Price/Book | 3.29 | EPS next 5Y | - | 52W High Chg | -72.00% |
| Recommedations | 1.00 | Quick Ratio | 2.32 | Shares Outstanding | 16.82M | 52W Low Chg | 35.00% |
| Insider Own | 7.30% | ROA | -33.57% | Shares Float | 15.61M | Beta | -1.11 |
| Inst Own | 17.12% | ROE | -65.28% | Shares Shorted/Prior | 563.37K/52.23K | Price | 1.46 |
| Gross Margin | 11.28% | Profit Margin | -110.40% | Avg. Volume | 41,004 | Target Price | - |
| Oper. Margin | -136.92% | Earnings Date | Oct 10 | Volume | 7,826 | Change | -2.01% |
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
| Aegis Capital | Buy | Oct 19, 20 |
| Aegis Capital | Buy | Sep 4, 20 |
| Aegis Capital | Buy | Aug 21, 20 |
| B. Riley Securities | Buy | Dec 17, 18 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Irani Zackary S. | Chief Executive Offi.. Chief Executive Officer | May 09 | Buy | 1.39 | 300 | 417 | 1,017,660 | 05/10/23 |
| Irani Zackary S. | Chief Executive Offi.. Chief Executive Officer | Apr 27 | Buy | 1.33 | 4,400 | 5,852 | 1,017,360 | 05/01/23 |
| Irani Zackary S. | Chief Executive Offi.. Chief Executive Officer | Apr 26 | Buy | 1.26 | 7,000 | 8,820 | 1,012,960 | 04/27/23 |
| BARBIERI ALLEN | Executive Vice Chair.. Executive Vice Chairman | Jan 27 | Buy | 2.94 | 1,538 | 4,522 | 101,327 | 01/31/23 |
| Coste Catherine | Director Director | Jan 26 | Buy | 2.96 | 2,190 | 6,482 | 43,790 | 01/30/23 |
| Irani Zackary S. | Chief Executive Offi.. Chief Executive Officer | Jan 25 | Buy | 2.85 | 1,800 | 5,130 | 1,005,960 | 01/26/23 |
| Irani Zackary S. | Chief Executive Offi.. Chief Executive Officer | Jan 24 | Buy | 2.81 | 2,000 | 5,620 | 1,004,160 | 01/25/23 |